DERMATA THERAPEUTICS, INC. (DRMA) earnings per share
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2025 | 2025-12-31 | -$8.16 | 2026-03-26 |
| FY 2024 | 2024-12-31 | -$80.32 | 2025-03-17 |
| FY 2023 | 2023-12-31 | -$399.90 | 2024-03-21 |
| FY 2022 | 2022-12-31 | — | 2023-02-21 |
| FY 2021 | 2021-12-31 | — | 2022-03-28 |
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.74 | 2026-08-11 |
| Q1 2026 | 2026-03-31 | -$0.48 | 2026-05-13 |
| Q4 2025 | 2025-12-31 | -$1.52 | 2026-03-26 |
| Q3 2025 | 2025-09-30 | -$1.65 | 2025-11-14 |
| Q2 2025 | 2025-06-30 | -$1.66 | 2025-08-13 |
| Q1 2025 | 2025-03-31 | -$4.47 | 2025-05-14 |
| Q4 2024 | 2024-12-31 | $21.86 | 2025-03-17 |
| Q3 2024 | 2024-09-30 | -$20.41 | 2024-11-13 |
| Q2 2024 | 2024-06-30 | -$41.82 | 2024-08-07 |
| Q1 2024 | 2024-03-31 | -$70.60 | 2024-05-15 |
| Q4 2023 | 2023-12-31 | — | 2024-03-21 |
| Q3 2023 | 2023-09-30 | — | 2023-11-09 |
| Q2 2023 | 2023-06-30 | — | 2023-08-10 |
| Q1 2023 | 2023-03-31 | — | 2023-05-11 |
| Q4 2022 | 2022-12-31 | — | 2023-02-21 |
| Q3 2022 | 2022-09-30 | — | 2022-11-10 |
| Q2 2022 | 2022-06-30 | — | 2022-08-15 |
| Q1 2022 | 2022-03-31 | — | 2022-05-16 |
| Q2 2021 | 2021-03-31 | — | 2021-09-27 |
| Q3 2021 | 2020-12-31 | — | 2021-11-15 |
| Period | End | FCF / Share | Filed |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$1.25 | 2026-08-11 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from
the matching 10-Q; Q4 is derived as full-year minus nine-month
YTD because XBRL doesn't tag Q4 as its own period.
EPS Basic and EPS Diluted
are reported directly by the filer.
FCF / Share is computed as
(Operating Cash Flow − Capital Expenditures) ÷ Diluted
Shares Outstanding. When SEC companyfacts omits the
direct diluted-share concept for an older period, we
imply it from NetIncomeLoss ÷ EarningsPerShareDiluted.
For financial filers whose operating cash flow includes
customer-fund activity (e.g. Mercado Pago deposits),
FCF may materially exceed net income because the fintech
float is recorded inside OCF under US GAAP.
Per-share values are split-adjusted
to the current share count (3 split
s since
2023).
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
DRMA CIK 0001853816 Source: EDGAR filings · all facts